BPC-157 raised questions about the evidentiary standard. KPV focused on characterization and what happens once “the box is open.” TB-500 carried both themes forward, but added another threshold issue: whether evidence involving full-length thymosin beta-4 can meaningfully support TB-500, a shorter and chemically distinct fragment.
TB-500 is an N-acetylated seven-amino-acid peptide containing the actin-binding sequence associated with thymosin beta-4, an endogenous protein involved in cell migration, angiogenesis, tissue remodeling, and wound repair. FDA emphasized that thymosin beta-4 and TB-500 are different substances with different properties.
That distinction became central because the formal human studies discussed by public commenters involved full-length thymosin beta-4—not TB-500 itself. One commenter supporting inclusion acknowledged the limitation directly: “The parent molecule experience is relevant to risk assessment, though not dispositive for the fragment.”
FDA again focused heavily again on an inconsistent and withdrawn nomination. The submission identified TB-500 free base, but the certificate of analysis related to TB-500 acetate, while other chemical identifiers did not clearly match either form. “TB-500” is also a common name rather than a recognized United States Adopted Name.
The proposed product was a three-milligram-per-milliliter lyophilized powder for subcutaneous or intramuscular injection. FDA claimed missing information involving impurities, aggregation, microbial bioburden, bacterial endotoxins, solubility, and other attributes necessary to evaluate an injectable product.
FDA also asserted that they found no published human pharmacokinetic studies, clinical studies, human exposure data, or nonclinical toxicity studies involving TB-500. An in vitro scratch model did not show wound closure with TB-500, although FDA acknowledged that the model only measured fibroblast migration and did not reproduce the full biological process of wound healing.
The Committee’s questioning made that finding more significant. FDA explained that full-length thymosin beta-4 was active in the model and that a related non-acetylated fragment also showed activity, but the nominated N-acetylated TB-500 did not. That raised a basic question about whether the chemical modification may alter the fragment’s biological activity.
Committee members also returned to dosing. One member noted that the same oral range—0.25 to 2 milligrams—had been cited for TB-500 and a completely different peptide. FDA confirmed that it had no clinical information supporting a dose, route, frequency, duration, or treatment protocol for TB-500, and no panel member could explain how those doses had been derived.
During Committee questioning, FDA discussed additional theoretical concerns involving immunogenicity and cancer biology. Full-length thymosin beta-4 has been associated in laboratory studies with migration and invasion of certain cancer cells. FDA was careful not to attribute those effects to TB-500, because no corresponding studies exist, but it also could not exclude the possibility. The same qualification applied to immunogenicity: there were no data demonstrating the risk, but injectable administration, impurities, and aggregation could increase it.
Public commenters responded with many of the same arguments made for BPC-157 and KPV: existing physician experience, substantial patient use, no clear adverse safety signal in the retrospective information presented, and the need to distinguish poor-quality products from the inherent characteristics of the peptide.
One physician argued that supervised clinical experience should not be dismissed as no evidence: “Hundreds of patients’ data is evidence.” Other speakers presented dispensing and complaint data, although those reports were observational and did not replace controlled studies.
The strongest public comments again involved product quality. An analytical chemist reported testing 46 peptide products obtained from seven vendors, of which only ten met label claim. Among the TB-500 samples, the speaker reported substantial potency deviations, and one purported TB-500 product reportedly contained an entirely different peptide. His proposed release standard was simple: “No confirmation, no release.”
Commenters proposed orthogonal identity confirmation, quantitative potency testing, defined impurity limits, residual-solvent and elemental-impurity testing, TFA testing, endotoxin and bioburden controls, sterility testing, qualified API sourcing, Drug Master Files, chain-of-custody documentation, physician monitoring, adverse-event reporting, and accreditation for pharmacies meeting enhanced standards.
USP representatives similarly pointed to existing standards addressing nomenclature, synthetic peptide analysis, and finished dosage-form quality. They emphasized that the submitted certificate of analysis lacked information expected for a synthetic peptide intended for injectable compounding.
The discussion then returned to how the missing human evidence could be developed. FDA explained that there is no agency filing fee for submitting an Investigational New Drug application and stated that products sourced from compounders have previously been permitted in IND studies. FDA’s position was that the IND pathway offers a lawful method for generating controlled human safety, exposure, and preliminary effectiveness data.
That led to one of the most important exchanges of the discussion.
A Committee member asked whether FDA had ever approved an injectable medication that had not previously been studied in humans. An FDA representative answered no. But that question concerned FDA approval of an injectable drug product—not whether a bulk substance could be placed on the 503A Bulks List.
A Committee member then raised the broader and more relevant question: has FDA previously placed a substance on the 503A Bulks List without human clinical-trial evidence? He pointed to thymol iodide, which FDA placed on the list in 2019 for topical use only. FDA could not answer the question definitively during the meeting. Agency representatives said they did not recall the details of the thymol iodide evaluation and clarified only that its listing was limited to topical administration.
That left a real ambiguity. FDA’s 2016 proposed rule—the analysis preceding thymol iodide’s inclusion in the 2019 final rule—stated that thymol iodide was well characterized, had reportedly been used without major complications, had more than 100 years of historical use, and had limited effectiveness data for topical wounds and ulcers. The published rulemaking analysis does not identify a formal human clinical trial as the basis for listing thymol iodide. FDA nevertheless included it after balancing characterization, reported safety experience, limited effectiveness evidence, and more than a century of historical use.
Thymol iodide is not a direct comparator to injectable TB-500. It was well characterized, had extensive historical use, and was restricted to a topical route. But the precedent raises an unresolved question: is FDA treating human clinical trials as a practical prerequisite for TB-500 and the other peptides even though the governing criteria refer to “available evidence” and do not expressly require a clinical trial?
One public commenter opposing immediate inclusion described TB-500 as “the weakest file in front of you today.” He acknowledged that the thymosin beta-4 literature was encouraging but emphasized that the evidence could not simply be carried over to an acetylated fragment that behaved differently in the limited study FDA identified.
That may be the most accurate description of the record. The rationale supporting TB-500 primarily comes from thymosin beta-4 studies, mechanistic theory, physician experience, retrospective reports, and substantial existing demand. FDA’s analysis focused on TB-500 itself and found no direct human studies, uncertain identity, incomplete injectable-quality information, unsupported dosing, and unresolved safety questions.
The central issue is therefore not simply whether clinical studies would be valuable. It is whether their absence should independently weigh against listing—or whether FDA has previously accepted other forms of evidence when balancing the four criteria. The thymol iodide question placed that issue directly before the Committee, but it was not resolved in the discussion.
The Committee ultimately voted 8–6 in favor, with one abstention, recommending TB-500’s inclusion on the 503A Bulks List.